Page 14 - Doha Declaration News Today

A small number of pharmaceutical companies with the support of developed country governments invested billions of dollars in research and development of COVID-19 vaccines, related medicines, and technologies including mRNA, DNA, RNA, viral vector, protein subunit and testing materials along with their production and distribution.

Trade bodies are dictating access to COVID-19 drugs. But will patent waivers increase production in the global South?

To embed, copy and paste the code into your website or blog: Or maybe not.  On April 30th, Ambassador Katherine Tai, U.S. Trade Representative (USTR), issued the 2021 Special 301 Report.  In a press release, the USTR stated that "[i]ntellectual property rights incentivize our creators, manufacturers, and innovators to invent new products and technologies."  The press release notes that the review period underlying the Report took place during the COVID-19 pandemic, "the largest global health...

The writer is a former SAPM Health. LIKE every crisis, the Covid-19 pandemic has also brought some opportunities, two in particular. First, it has spurred innovation. In relatively no time, experimental vaccines started queuing up. The mRNA-based vaccine was developed which is a watershed innovation. This is going to profoundly change the future of prevention and therapeutics. Regulatory pathways for emergency use authorisation for these vaccines have also worked well. Second, on May 5, the US ...

The AIDS fight offers a COVID vaccine patent pathway Updated: Updated: May 22, 2021 07:30 IST There are recognised ways to overcome the patents hurdle, ensuring social justice and boosting the COVID-19 battle Share Article AAA There are recognised ways to overcome the patents hurdle, ensuring social justice and boosting the COVID-19 battle In order to achieve global herd immunity and prevent new strains of COVID-19 from emerging, possibly for years to come, vaccines need to be affordable and...

Vaccine IPR waiver may end up being just US posturing By Liu Hui | China Daily | Updated: 2021-05-19 07:21 Since the outbreak of the novel coronavirus pandemic, international organizations, such as the United Nations, and developing countries have been calling on Big Pharma to waive intellectual property protection for COVID-19 vaccines, so as to increase vaccine production and ensure equitable vaccine distribution across the world. Under increasing international ...

consensus among member states. The European Commission said it would begin discussions on waivers but Germany, home to BioNTech, the firm that created the vaccine being marketed by Pfizer, said it opposed a waiver because “the protection of the intellectual property is a source of innovation and must remain so”. However, the Indian government has taken a different line domestically: At a hearing in India’s Supreme Court this month, the court asked the government whether it intended to i...

Read more about Patent waver for Covid vaccine without tech transfer wont speed up supply on Business Standard. Intellectual property rights (IPR) on drugs and vaccine formulae give creators an exclusive right over inventions for a certain period of time, and prevent pharmaceutical companies from making it.

The global response to the Covid-19 pandemic has replicated the tragic mistakes of the HIV/AIDS epidemic, dividing the world between those who can access vaccines and treatments, and those who cannot. Today the European Parliament will hold a debate on “Accelerating progress and tackling inequalities towards ending AIDS as a public health threat by 2030”. The human right to health should always take precedence over rules on Trade-Related aspects of Intellectual Property Rights (TRIPS). This...

If India issues compulsory licences saying it is entitled to do so, it should expect retaliation from abroad